Long-Term Effectiveness of Human Papillomavirus Vaccination: Implications for Future Reduction in Cancer
Authors: Rebecca B. Perkins, Debbie Saslow, Kristin Oliver
Journal: Annals of Internal Medicine (2022)

EditorialsJuly 2022Long-Term Effectiveness of Human Papillomavirus Vaccination: Implications for Future Reduction in CancerRebecca B. Perkins, MD, MSc, Debbie Saslow, PhD, Kristin Oliver, MD, MHSRebecca B. Perkins, MD, MScDepartment of Obstetrics and Gynecology, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts, Debbie Saslow, PhDPrevention and Early Detection Department, American Cancer Society, Atlanta, Georgia, Kristin Oliver, MD, MHSDepartment of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, New YorkAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M22-1309 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Infection with human papillomavirus (HPV) is associated with 6 cancer types: cervical squamous cell carcinoma and adenocarcinoma, as well as oropharyngeal, anal, vulvar, vaginal, and penile squamous cell carcinoma. Although rates of cervical cancer decreased after the adoption of population-level screening programs, a recent study found a 2.36% annual increase in all HPV-related cancer types between 2001 and 2017 in the United States, with an incidence of HPV-associated cancer of 13.68 cases per 100 000 among women and 11 cases per 100 000 among men (1). For cervical cancer, we have effective screening programs and treatments of cervical precancer, but significant disparities ...References1. Liao CI, Francoeur AA, Kapp DS, et al. Trends in human papillomavirus-associated cancers, demographic characteristics, and vaccinations in the US, 2001-2017. JAMA Netw Open. 2022;5:e222530. [PMID: 35294540] doi:10.1001/jamanetworkopen.2022.2530 CrossrefMedlineGoogle Scholar2. Fuzzell LN, Perkins RB, Christy SM, et al. Cervical cancer screening in the United States: challenges and potential solutions for underscreened groups. Prev Med. 2021;144:106400. [PMID: 33388330] doi:10.1016/j.ypmed.2020.106400 CrossrefMedlineGoogle Scholar3. Rosenblum HG, Lewis RM, Gargano JW, et al. Human papillomavirus vaccine impact and effectiveness through 12 years after vaccine introduction in the United States, 2003 to 2018. Ann Intern Med. 2022;175:918-26. doi:10.7326/M21-3798 LinkGoogle Scholar4. Brisson M, Bénard É, Drolet M, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016;1:e8-e17. [PMID: 29253379] doi:10.1016/S2468-2667(16)30001-9 CrossrefMedlineGoogle Scholar5. Lei J, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383:1340-1348. [PMID: 32997908] doi:10.1056/NEJMoa1917338 CrossrefMedlineGoogle Scholar6. Lehtinen M, Lagheden C, Luostarinen T, et al. Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial. BMJ Open. 2021;11:e050669. [PMID: 35149535] doi:10.1136/bmjopen-2021-050669 CrossrefMedlineGoogle Scholar7. Yuill S, Egger S, Smith M, et al. Has human papillomavirus (HPV) vaccination prevented adverse pregnancy outcomes? Population-level analysis after 8 years of a national HPV vaccination program in Australia. J Infect Dis. 2020;222:499-508. [PMID: 32386228] doi:10.1093/infdis/jiaa106 CrossrefMedlineGoogle Scholar8. Pingali C, Yankey D, Elam-Evans LD, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years — United States, 2020. MMWR Morb Mortal Wkly Rep. 2021;70:1183-1190. [PMID: 34473682] doi:10.15585/mmwr.mm7035a1 CrossrefMedlineGoogle Scholar9. Saxena K, Marden JR, Carias C, et al. Impact of the COVID-19 pandemic on adolescent vaccinations: projected time to reverse deficits in routine adolescent vaccination in the United States. Curr Med Res Opin. 2021;37:2077-2087. [PMID: 34538163] doi:10.1080/03007995.2021.1981842 CrossrefMedlineGoogle Scholar10. Gilkey MB, Bednarczyk RA, Gerend MA, et al. Getting human papillomavirus vaccination back on track: protecting our national investment in human papillomavirus vaccination in the COVID-19 era. J Adolesc Health. 2020;67:633-634. [PMID: 32933839] doi:10.1016/j.jadohealth.2020.08.013 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Department of Obstetrics and Gynecology, Boston University School of Medicine and Boston Medical Center, Boston, MassachusettsPrevention and Early Detection Department, American Cancer Society, Atlanta, GeorgiaDepartment of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, New YorkDisclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M22-1309.Corresponding Author: Rebecca B. Perkins, MD, MSc, 775 Albany Street, Dowling Building, 4th Floor, Boston, MA 02118; e-mail, [email protected]edu.This article was published at Annals.org on 17 May 2022. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHuman Papillomavirus Vaccine Impact and Effectiveness Through 12 Years After Vaccine Introduction in the United States, 2003 to 2018 Hannah G. Rosenblum , Rayleen M. Lewis , Julia W. Gargano , Troy D. Querec , Elizabeth R. Unger , and Lauri E. Markowitz Metrics July 2022Volume 175, Issue 7Page: 1037-1038KeywordsAdolescentsCancer preventionCervical cancerHuman papillomavirusPrevention, policy, and public healthSquamous cell carcinomaVaccines ePublished: 17 May 2022 Issue Published: July 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...